Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin PEDD-PRVI in advanced pancreatic adenocarcinoma
NCT04270929Phase 1Withdrawn
- Sponsor
- Roger Williams Medical Center
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Roger Williams Medical Center. Planned start Dec 2019; status: withdrawn.
02
Drugs
oxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04270929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270929.